Pharmacokinetics and clinical use of drotrecogin alfa (activated) in patients with severe sepsis

Pharmacotherapy

Volumn 22, Issue 12 II, 2002, Pages

  Olsen, Keith M ^b   Martin, Steven J ^a  

^a UNIVERSITY OF TOLEDO   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; HEPARIN;

ABDOMINAL BLEEDING; AGE; ANTIBODY PRODUCTION; ANTICOAGULATION; BLEEDING; BODY WEIGHT; BRAIN HEMORRHAGE; CAUSE OF DEATH; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; ECCHYMOSIS; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; GENITAL BLEEDING; HEMATEMESIS; HEMATOCRIT; HEMATOMA; HEMATURIA; HEMODIALYSIS; HUMAN; INFLAMMATION; INTERNATIONAL STANDARD UNIT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER INJURY; LUNG HEMORRHAGE; NONHUMAN; PATIENT MONITORING; PHARMACIST; PLASMA CLEARANCE; PROTEIN PROCESSING; PURPURA; RASH; RETROPERITONEAL HEMORRHAGE; REVIEW; SEPSIS; SEX; SKIN BLEEDING; THORAX INJURY; THROMBOCYTE COUNT; TREATMENT CONTRAINDICATION; ULCER; VEIN THROMBOSIS;

EID: 0036895366     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.18.196s.33708     Document Type: Review

References (13)

1. Yan SB, Dhainaut JF. Activated protein C in severe sepsis. Crit Care Med 2001;29(suppl):S69-74.
2. Bernard GR, Ely W, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29:2051-9.
3. U.S. Food and Drug Administration. Briefing Document for Xigris for the Treatment of Severe Sepsis. Anti-Infective Drugs Advisory Committee meetings page. Available from www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_02_ fdabriefing.doc. Accessed September 12, 2001.
4. Bernard GR, Vincent JL, Laterre PF, et al, for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
5. Eli Lilly & Co. Data on File. Indianapolis, IN; 2001.
6. Small D, Seger M, Dhainaut JF. Pharmacokinetics of recombinant human activated protein C in patients with severe sepsis: subgroup analyses [abstr]. Chest 2001;120[suppl]:S157.
7. Robbins MF, Joyce DE, Small DS. Pharmacokinetic parameters of recombinant human activated protein C (drotrecogin alfa [activated]) in patients with severe sepsis [abstr]. Am J Health-Syst Pharm 2001;58(20):1975.
8. Fourrier F, Chopin C, Goudeman J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-23.
9. Pastan S, Bailey J. Dialysis therapy. N Engl J Med 1998;338:1428-37.
10. Forni LG, Hilton PJ. Continuous hemofiltration in the treatment of acute renal failure. N Engl J Med 1997;336: 1303-9.
11. Eli Lilly, Inc. Xigris (Drotrecogin Alfa [Activated]) Prescribing Information. Indianapolis, IN; 2001.
12. Howey DC, Hartman DL. Preparation for trials of recombinant activated protein C in sepsis: A pharmacokinetic and dynamic stud), in healthy men and women [abstr]. Chest 1997;112(suppl 3):S89.
13. Grinnel BW. Native and modified recombinant human protein C: function, secretion and posttranslational modifications. In: Bruley D, Drohan W, eds. Protein C and Telated Anticoagulants. Houston: Gulf Publishing, 1990:30-63.